The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

Green, David; Southern, Jo; Andrews, Nick; Ashton, Lindsey; Burbidge, Polly; Woodgate, Sarah; Pebody, Richard; Miller, Elizabeth

doi:10.1086/606046

Cited by 138 publications

(72 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We were also able to compare the natural levels of functional antibodies to functional antibodies measured following the administration of conjugate or polysaccharide vaccines in infants and adults, respectively, in the United Kingdom (16,17).…”

mentioning

confidence: 99%

Streptococcus pneumoniae Serotype 1 Burden in the African Meningitis Belt: Exploration of Functionality in Specific Antibodies

Blumental¹,

Moïsi²,

Roalfe³

et al. 2015

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

f Streptococcus pneumoniae serotype 1 (Sp1) constitutes an important cause of seasonal endemic meningitis in all age groups in the African meningitis belt. Despite a higher meningitis incidence, the Burkinabé population has an Sp1-specific antibody seroprevalence similar to that reported in the United Kingdom (UK). We aimed to establish whether the opsonophagocytic activity (OPA) of pneumococcal IgG naturally present in Burkina Faso differs from that seen in individuals in the UK and to compare the OPAs generated by natural and vaccine-induced immunity. Samples collected from pneumococcal vaccine-naive Burkinabé and UK subjects were matched for age (1 to 39 years) and anti-Sp1 IgG level, analyzed for OPA to 3 S. pneumoniae serotypes (1, 5, and 19A), and compared to postvaccine samples. Furthermore, the Burkinabé samples were assessed for IgG avidity and serotype-specific IgM concentrations. One hundred sixty-nine matched serum samples from both populations were selected. A greater proportion of Burkinabé subjects aged 1 to 19 years had functional Sp1 activity (OPA > 8) compared to UK subjects (12% versus 2%, P < 0.001); however, the proportions were similar among adults (9%). The correlation between Sp1 IgG concentration and OPA was good (P < 0.001), but many individuals had nonfunctional IgG, which was not related to avidity. While the Sp1 IgM concentrations correlated with OPA, not all of the function in serum samples with low IgG could be attributed to IgM. Finally, vaccine-induced Sp1-specific IgG was more functional than equivalent amounts of naturally occurring IgG. In conclusion, despite a substantially higher pneumococcal meningitis incidence, no decreased functional immunity to Sp1 could be evidenced in the Burkinabé population compared to that in the population from the UK. Furthermore, the naturally induced antibodies were less functional than vaccine-induced antibodies.

show abstract

mentioning

confidence: 99%

Streptococcus pneumoniae Serotype 1 Burden in the African Meningitis Belt: Exploration of Functionality in Specific Antibodies

Blumental¹,

Moïsi²,

Roalfe³

et al. 2015

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…Although several smaller earlier studies did not show that priming with pneumococcal conjugate vaccine followed by polysaccharide vaccine enhanced immunogenicity, more recent larger studies showed improved response (72)(73)(74). These larger studies using PCV13 conjugate vaccine followed a year later by the polysaccharide-based PPSV23 resulted in higher antibody activities after a month of PPSV23 administration, but at 6 months the antibody levels in booster recipients fall to baseline (66,75).…”

Section: Focused Reviewsmentioning

confidence: 92%

Pneumococcal Vaccination Strategies. An Update and Perspective

et al. 2016

View full text Add to dashboard Cite

Streptococcus pneumoniae is an important global pathogen that causes a wide range of clinical disease in children and adults. Pneumococcal pneumonia is by far the common presentation of noninvasive and invasive pneumococcal disease and affects the young, the elderly, and the immunocompromised disproportionately. Patients with chronic pulmonary diseases are also at higher risk for pneumococcal infections. Substantial progress over the century has been made in the understanding of pneumococcal immunobiology and the prevention of invasive pneumococcal disease through vaccination. Currently, two pneumococcal vaccines are available for individuals at risk of pneumococcal disease: the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal protein-conjugate vaccine (PCV13). The goal of pneumococcal vaccination is to stimulate effective antipneumococcal antibody and mucosal immunity response and immunological memory. Vaccination of infants and young children with pneumococcal conjugate vaccine has led to significant decrease in nasal carriage rates and pneumococcal disease in all age groups. Recent pneumococcal vaccine indication and schedule recommendations on the basis of age and risk factors are outlined in this Focused Review. As new pneumococcal vaccine recommendations are being followed, continued efforts are needed to address the vaccine efficacy in the waning immunity of the ever-aging population, the implementation of vaccines using two different vaccines under very specific schedules and their real world clinical and cost effectiveness, and the development of next generation pneumococcal vaccines.

show abstract

“…9 Some immunological studies 10 have suggested improved immunogenicity of PCV7 over PPV23 in adults and/or the elderly. [11][12][13][14][15] while others have reported no significant differences. 10,[16][17][18][19] In 2014 the first large clinical trial of PCV13 in the adults aged >65 y (CAPiTA trial -Community Acquired Pneumonia Immunization Trial in Adults 20 ) was completed.…”

Section: Introductionmentioning

confidence: 93%

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

Dirmesropian

Wood

MacIntyre

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature review was conducted. The majority of the studies identified (9 out of 10) found that PCV13 was costeffective in adults and/or the elderly. However, these results were based on assumptions that could not always be informed by robust evidence. Key uncertainties included the efficacy of PCV13 against non-invasive pneumonia and the herd immunity effect of childhood vaccination programs. Emerging trial evidence on PCV13 in adults from the Netherlands offers the ability to parameterize future economic evaluations with empirical efficacy data. However, it is important that these estimates are used thoughtfully when they are transferred to other settings.

show abstract

The Immunogenicity of 7‐Valent Pneumococcal Conjugate Vaccine versus 23‐Valent Polysaccharide Vaccine in Adults Aged 50–80 Years

Abstract: http://www.clinicaltrials.gov/NCT00197821.

Cited by 138 publications

References 23 publications

Streptococcus pneumoniae Serotype 1 Burden in the African Meningitis Belt: Exploration of Functionality in Specific Antibodies

Streptococcus pneumoniae Serotype 1 Burden in the African Meningitis Belt: Exploration of Functionality in Specific Antibodies

Pneumococcal Vaccination Strategies. An Update and Perspective

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly

Contact Info

Product

Resources

About